Alnylam Pharma stock analysis
Alnylam Pharma (DUL) Stock Price & Analysis
DUL Stock Chart & Stats
- Day’s Range
- CHF 138.58 - CHF 138.58
- 52-Week Range
- CHF 128.02 - CHF 274.18
- Previous Close
- CHF 138.58
- Volume
- N/A
- Average Volume (3M)
- 4
- Market Cap
- CHF 16.76B
- Enterprise Value
- CHF 33.47B
- Total Cash (Recent Filing)
- CHF 3.59B
- Total Debt (Recent Filing)
- CHF 1.26B
- Price to Earnings (P/E)
- 7.4
- Beta
- -0.64
- Next Earnings
- Feb 18, 2027 (Est.)
- EPS Estimate
- 1.42
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
TTR Franchise Growth
Rapid TTR revenue growth shows strong commercial traction for Alnylam’s marketed franchise and expanding demand in ATTR cardiomyopathy. Continued uptake provides a durable revenue base, while scale can support investment in additional RNAi medicines and broader patient access.
RNAi Clinical And Commercial Differentiation
Clinical outcome evidence and a convenient quarterly dosing profile strengthen AMVUTTRA’s differentiation in a serious rare disease. These characteristics can support physician adoption, patient persistence, and the company’s ability to build a lasting position in TTR treatment.
Cash Generation And Financial Capacity
Strong operating and free cash flow gives Alnylam internal funding capacity for clinical development, commercialization, and pipeline expansion. Free cash flow representing about 86% of net income also supports the durability of the current profitability inflection and strategic flexibility.
Bears Say
Slower AMVUTTRA Patient Conversion
Slower conversion of physician interest into patient starts may delay the realization of AMVUTTRA’s commercial opportunity. If newer prescribers remain less familiar with ATTR-CM or have limited eligible patients, growth investment may produce a more gradual and costly ramp.
Margin And Collaboration Revenue Pressure
Higher royalty costs are reducing product gross margin, while collaboration revenue can be volatile after a prior one-time Roche milestone. This mix creates pressure on earnings quality and makes reported operating performance more dependent on product scale and recurring sales.
Commercial Leadership Transition
A change in commercial leadership adds execution risk while Alnylam is still working to improve AMVUTTRA conversion and prepare future launches. Transition time could disrupt accountability or go-to-market momentum, even though the existing organization provides a foundation for continuity.
Alnylam Pharma News
DUL FAQ
What was Alnylam Pharma’s price range in the past 12 months?
What is Alnylam Pharma’s market cap?
When is Alnylam Pharma’s upcoming earnings report date?
How were Alnylam Pharma’s earnings last quarter?
Is Alnylam Pharma overvalued?
Does Alnylam Pharma pay dividends?
What is Alnylam Pharma’s EPS estimate?
How many shares outstanding does Alnylam Pharma have?
What happened to Alnylam Pharma’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Alnylam Pharma?
What is the TipRanks Smart Score and how is it calculated?
Alnylam Pharma Stock Smart Score
Company Description
Alnylam Pharma
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Yvonne L. Greenstreet
- Employees
- 2,500
- Website
- www.alnylam.com
- Address
- 675 West Kendall Street, Cambridge, MA, 02142, US
Alnylam Pharma (DUL) Earnings & Revenues
DUL Company Deck
DUL Earnings Call
Earnings Call SentimentPositive
The call was broadly positive, with strong product and TTR revenue growth, expanding AMVUTTRA adoption, broad patient access, encouraging brezosiran data, a growing pipeline, profitability, and substantial cash generation. However, management acknowledged that AMVUTTRA demand growth and conversion of physician engagement into patient starts are slower than expected, while 340B policy uncertainty, Medicare Advantage access changes, lower collaboration revenue, lower gross margin, and the need to enlarge the TRITON-CM study remain challenges.
View all CH:DUL earnings summariesDUL Net sales Breakdown
- 67.90% Net product revenues
- 29.87% Net revenues from collaborations
- 2.22% Royalty revenue
DUL Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 1 | 12 |
| Technical Analysis | 6 | 1 | 3 |
| Moving Averages | 1 | 0 | 9 |
